Pharma company Strides Arcolab has posted a 47-fold increase in net profit to ₹3,525 crore for the quarter ended December, 2013, against ₹73.93 crore in the corresponding period last year.
The massive increase in net profit is due to completing the $1.5-billion Agila Specialities sale to Mylan Inc during the quarter.
In a press statement, the company said its revenues grew 21 per cent to ₹276 crore. The company also said that it has extended its financial year by another three months to March 2014.
GuidanceIt gave a guidance of ₹280 crore for the extended quarter. “This has been a defining quarter for all of us at Strides as we delivered significant value to all stakeholders post the successful completion of the Agila transaction,” said Arun Kumar, Vice-Chairman.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.